Reports

As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Phosphoinositide 3-Kinase Inhibitors Market: By Application: CLL - Chronic lymphocytic leukaemia, FL - Follicular lymphoma; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics: SWOT Analysis; Porter’s Five Forces Analysis; Competitive Landscape; Industry Events and Developments

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook

The global phosphoinositide 3-kinase (PI3K) inhibitors market is projected to grow at a CAGR of 4.65% over the forecast period of 2021-2026.

 

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Targeted therapy for small molecules uses PI3K inhibitors that are relatively new in the area of oncology treatment. The development in the field of targeted therapy and their approvals are driving the growth of the industry globally. The governments across the nations have taken various measures to cut down the cost of these drugs to help patients. Such programmes help patients receive treatment at an affordable price. Thus, the emergence of such reimbursement schemes is one of the key market developments that will fuel the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.

 

Properties and Applications

A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a therapeutic drug class that works by inhibiting one or more of the 3-kinase phosphoinositide enzymes.

 

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market By Application

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The global phosphoinositide 3-kinase (PI3K) inhibitors industry can be broadly categorised based on its applications and regions.

  • Application
    • CLL - Chronic Lymphocytic Leukaemia
    • FL - Follicular Lymphoma
    • Others

The EMR report looks into the regional phosphoinositide 3-kinase (PI3K) inhibitors markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The rising prevalence of cancer around the globe has resulted in the increased demand for chemotherapy and other treatment procedures. Chemotherapy drugs play a significant role in treating cancer. Their drawbacks, however, have produced a change from conventional chemotherapy to targeted therapies. As a result, extensive ongoing research is being performed on targeted therapies such as PI3K inhibitors with demonstrated effectiveness in oncology applications. Significant R&D has contributed to tailored treatments in the dominant therapeutic category. Thus, the recent launches and approvals of targeted therapy during the forecast period will contribute to the growth of phosphoinositide 3-kinase (PI3K) inhibitors industry globally. Although the complex manufacturing process of such drugs makes them expensive, which is becoming a significant challenge for manufacturers and may hamper the industry growth over the forecast period.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global phosphoinositide 3-kinase (PI3K) inhibitors market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Bayer AG
  • Gilead Sciences Inc.
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.
  • Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2016-2020
Forecast Period 2021-2026
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Application, Region
Breakup by Application CLL - Chronic lymphocytic leukaemia, FL - Follicular lymphoma
Breakup by Region North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Bayer AG, Gilead Sciences, Inc., Novartis AG, TG Therapeutics, Inc., Verastem, Inc., Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market (2016-2020) 
    8.3    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast (2021-2026)
    8.4    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Application
        8.4.1    CLL - Chronic lymphocytic leukaemia
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2016-2020)
            8.4.1.3    Forecast Trend (2021-2026)
        8.4.2    FL - Follicular lymphoma
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2016-2020)
            8.4.2.3    Forecast Trend (2021-2026)
    8.5    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Region
        8.5.1    Market Share
            8.5.1.1    North America
            8.5.1.2    Europe
            8.5.1.3    Asia Pacific
            8.5.1.4    Latin America
            8.5.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2016-2020)
        9.1.2    Forecast Trend (2021-2026)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2016-2020)
        9.2.2    Forecast Trend (2021-2026)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2016-2020)
        9.3.2    Forecast Trend (2021-2026)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2016-2020)
        9.4.2    Forecast Trend (2021-2026)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2016-2020)
        9.5.2    Forecast Trend (2021-2026)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Competitive Landscape
    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    Bayer AG 
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Gilead Sciences, Inc.
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    Novartis AG
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    TG Therapeutics, Inc.
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    Verastem, Inc.
            11.2.5.1    Company Overview
            11.2.5.2    Product Portfolio
            11.2.5.3    Demographic Reach and Achievements
            11.2.5.4    Certifications
        11.2.6    Others
12    Industry Events and Developments


List of Figures and Tables

1.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Key Industry Highlights, 2016 and 2026
2.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Application (USD Million), 2016-2020
3.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Application (USD Million), 2021-2026
4.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Region (USD Million), 2016-2020
5.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Region (USD Million), 2021-2026
6.    North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2016-2020
7.    North America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2021-2026
8.    Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2016-2020
9.    Europe Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2021-2026
10.    Asia Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2016-2020
11.    Asia Pacific Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2021-2026
12.    Latin America Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2016-2020
13.    Latin America Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2021-2026
14.    Middle East and Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Historical Market: Breakup by Country (USD Million), 2016-2020
15.    Middle East and Africa Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Forecast: Breakup by Country (USD Million), 2021-2026
16.    Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Structure

Key Questions Answered in the Report

The global phosphoinositide 3-kinase (PI3K) inhibitors market is projected to grow at a CAGR of 4.65% between 2021 and 2026.

The major drivers of the industry, such as the rising prevalence of cancer, growing demand for targeted therapies, favourable government initiatives, and growing technological advancements, are expected to aid the market growth.

The key market trends guiding the growth of the phosphoinositide 3-kinase (PI3K) inhibitors industry include the ongoing research activities and fresh approval of targeted therapies.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

CLL (chronic lymphocytic leukaemia) and FL (follicular lymphoma) are the leading applications of phosphoinositide 3-kinase (PI3K) inhibitors in the industry.

The major players in the industry are Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc., among others.

Analyst Review

The global phosphoinositide 3-kinase (PI3K) inhibitors market is being driven by the growing cases of cancer, reimbursement schemes, and the growing demand for chemotherapy. Aided by the growing research and development activities, the market is expected to witness a healthy growth in the forecast period of 2021-2026, growing at a CAGR of 4.65%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on applications, the phosphoinositide 3-kinase (PI3K) inhibitors industry can be segmented into CLL (chronic lymphocytic leukaemia) and FL (follicular lymphoma). The major regional markets for phosphoinositide 3-kinase (PI3K) inhibitors are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER